Literature DB >> 15078957

Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency.

Xiaoping Cui1, Lucy F Lee, Willie M Reed, Hsing-Jien Kung, Sanjay M Reddy.   

Abstract

Marek's disease, a lymphoproliferative disease of chickens, is caused by an alphaherpesvirus, Marek's disease virus (MDV). This virus encodes a virokine, vIL-8, with general homology to cellular CXC chemokines such as interleukin-8 (IL-8) and Gro-alpha. To study the function of vIL-8 gene, we deleted both copies of vIL-8 residing in the terminal repeat long and internal repeat long region of the viral genome and generated a mutant virus with vIL-8 deleted, rMd5/DeltavIL-8. Growth kinetics study showed that vIL-8 gene is dispensable for virus replication in cell culture. In vivo, the vIL-8 gene is involved in early cytolytic infections in lymphoid organs, as evidenced by limited viral antigen expression of rMd5/DeltavIL-8. However, the rMd5/DeltavIL-8 virus is unimpaired in virus replication in the feather follicle epithelium. vIL-8 does not appear to be important for establishment of latency, since rMd5/DeltavIL-8 and the wild-type virus have similar viremia titers at 14 days postinfection, a period when the virus titer comes primarily from reactivated latent genomes. Nevertheless, because of the impaired cytolytic infections, the overall transformation efficiency of the virus with vIL-8 deleted is much lower, as reflected by the reduced number of transformed cells at 5 weeks postinoculation and the presence of fewer gross tumors. Importantly, the revertant virus that restored the expression of vIL-8 gene also restored the wild-type phenotype, indicating the deficient phenotypes are results of vIL-8 deletion. One of the interesting differences between the MDV vIL-8 gene and its cellular counterpart is the presence of a DKR (Asp-Lys-Arg) motif instead of ELR (Glu-Leu-Arg) preceding the invariable CXC motif. To study the significance of this variation, we generated recombinant MDV, rMd5/vIL-8-ELR, carrying the ELR motif. Both in vitro and in vivo studies revealed that the DKR motif is as competent as ELR in pathogenesis of MDV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078957      PMCID: PMC387696          DOI: 10.1128/jvi.78.9.4753-4760.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  The genomes of the human herpesviruses: contents, relationships, and evolution.

Authors:  D J McGeoch
Journal:  Annu Rev Microbiol       Date:  1989       Impact factor: 15.500

2.  Attenuated revertant serotype 1 Marek's disease viruses: safety and protective efficacy.

Authors:  R L Witter
Journal:  Avian Dis       Date:  1991 Oct-Dec       Impact factor: 1.577

3.  Marek's disease virus gene clones encoding virus-specific phosphorylated polypeptides and serological characterization of fusion proteins.

Authors:  Z Z Cui; D Yan; L F Lee
Journal:  Virus Genes       Date:  1990-04       Impact factor: 2.332

4.  Gene sequence and mapping data from Marek's disease virus and herpesvirus of turkeys: implications for herpesvirus classification.

Authors:  A E Buckmaster; S D Scott; M J Sanderson; M E Boursnell; N L Ross; M M Binns
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

5.  Transfection of chicken embryo fibroblasts with Marek's disease virus DNA.

Authors:  R W Morgan; J L Cantello; C H McDermott
Journal:  Avian Dis       Date:  1990 Apr-Jun       Impact factor: 1.577

6.  Comparative pathogenesis studies with oncogenic and nononcogenic Marek's disease viruses and turkey herpesvirus.

Authors:  B W Calnek; J C Carlisle; J Fabricant; K K Murthy; K A Schat
Journal:  Am J Vet Res       Date:  1979-04       Impact factor: 1.156

7.  Latent infections with Marek's disease virus and turkey herpesvirus.

Authors:  B W Calnek; W R Shek; K A Schat
Journal:  J Natl Cancer Inst       Date:  1981-03       Impact factor: 13.506

8.  Monoclonal-antibody-mediated enzyme-linked immunosorbent assay for detection of reticuloendotheliosis viruses.

Authors:  Z Z Cui; L F Lee; E J Smith; R L Witter; T S Chang
Journal:  Avian Dis       Date:  1988 Jan-Mar       Impact factor: 1.577

9.  Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease.

Authors:  B W Calnek; K A Schat; M C Peckham; J Fabricant
Journal:  Avian Dis       Date:  1983 Jul-Sep       Impact factor: 1.577

10.  Selective cleavage of human DNA: RecA-assisted restriction endonuclease (RARE) cleavage.

Authors:  L J Ferrin; R D Camerini-Otero
Journal:  Science       Date:  1991-12-06       Impact factor: 47.728

View more
  23 in total

1.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication.

Authors:  Blanca Lupiani; Lucy F Lee; Xiaoping Cui; Isabel Gimeno; Amy Anderson; Robin W Morgan; Robert F Silva; Richard L Witter; Hsing-Jien Kung; Sanjay M Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

3.  Characterization of a very virulent Marek's disease virus mutant expressing the pp38 protein from the serotype 1 vaccine strain CVI988/Rispens.

Authors:  Lucy F Lee; Xiaoping Cui; Zhizhong Cui; Isabel Gimeno; Blanca Lupiani; Sanjay M Reddy
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

Review 4.  Alphaherpesviruses and chemokines: pas de deux not yet brought to perfection.

Authors:  Gerlinde R Van de Walle; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder; Venugopal K Nair; Karel A Schat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Melanie M Brinkmann; Marcel Pietrek; Oliver Dittrich-Breiholz; Michael Kracht; Thomas F Schulz
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Multiple alternative splicing to exons II and III of viral interleukin-8 (vIL-8) in the Marek's disease virus genome: the importance of vIL-8 exon I.

Authors:  Keith William Jarosinski; Karel Antoni Schat
Journal:  Virus Genes       Date:  2006-08-22       Impact factor: 2.332

8.  vLIP, a viral lipase homologue, is a virulence factor of Marek's disease virus.

Authors:  Jeremy P Kamil; B Karsten Tischer; Sascha Trapp; Venugopal K Nair; Nikolaus Osterrieder; Hsing-Jien Kung
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  Molecular and pathogenicity characterization of Gallid herpesvirus 2 newly isolated in China from 2009 to 2013.

Authors:  Yan-Ping Zhang; Hong-Chao Lv; Ke-Yan Bao; Yu-Long Gao; Hong-Lei Gao; Xiao- le Qi; Hong-Yu Cui; Yong-Qiang Wang; Kai Li; Li Gao; Xiao-Mei Wang; Chang-Jun Liu
Journal:  Virus Genes       Date:  2015-11-26       Impact factor: 2.332

10.  Deletion of the Marek's disease virus UL41 gene (vhs) has no measurable effect on latency or pathogenesis.

Authors:  Isabel Gimeno; Robert F Silva
Journal:  Virus Genes       Date:  2008-03-01       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.